Anterogen.Co.,Ltd. (KOSDAQ:065660)
15,410
+280 (1.85%)
Sep 1, 2026, 3:30 PM KST
Anterogen.Co.,Ltd. Revenue
Anterogen.Co.,Ltd. had revenue of 2.20B KRW in the quarter ending June 30, 2026, with 16.53% growth. This brings the company's revenue in the last twelve months to 8.37B, up 16.55% year-over-year. In the year 2025, Anterogen.Co.,Ltd. had annual revenue of 7.54B with 8.71% growth.
Revenue (ttm)
8.37B
Revenue Growth
+16.55%
P/S Ratio
18.09
Revenue / Employee
n/a
Employees
n/a
Market Cap
151.39B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.54B | 603.60M | 8.71% |
| Dec 31, 2024 | 6.93B | 432.62M | 6.66% |
| Dec 31, 2023 | 6.50B | -90.76M | -1.38% |
| Dec 31, 2022 | 6.59B | -1.53B | -18.85% |
| Dec 31, 2021 | 8.12B | 3.97B | 95.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bioneer | 338.01B |
| GC Cell | 163.35B |
| HLB Therapeutics | 64.45B |
| GC Genome | 32.64B |
| Prestige BioPharma | 16.21B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
| MedPacto | 4.99B |